Study of TRC102 in Combination With Pemetrexed in Cancer Patients
NCT ID: NCT00692159
Last Updated: 2010-09-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
28 participants
INTERVENTIONAL
2008-06-30
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Dose finding single arm
TRC102 + pemetrexed
Oral TRC102 solution + IV pemetrexed
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
TRC102 + pemetrexed
Oral TRC102 solution + IV pemetrexed
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patient is willing and able to abide by the protocol
* The patient has cancer and curative therapy is unavailable or standard therapy has failed
* The patient is at least 18 years of age
* The patient has adequate ability to perform activities of daily living
* The patient has recovered from significant toxicities of previous therapy
* The patient has adequate organ function as assessed by laboratory testing
Exclusion Criteria
* The patient is currently on treatment on another therapeutic clinical trial or has received an investigational drug within 4 weeks prior to first dose on this study
* The patient has had prior surgery, radiation or systemic therapy within 4 weeks of starting the study
* The patient has a history of CNS cancer
* The patient has an unstable medical condition including (not limited to) cardiac disease, HIV/AIDS, history of stroke, hepatitis or significant paricardial, pleural or peritoneal effusion
* The patient is pregnant or breastfeeding
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tracon Pharmaceuticals Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
TRACON Pharmaceuticals Inc.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Bryan Leigh, MD
Role: STUDY_DIRECTOR
Tracon Pharmaceuticals Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Scottsdale, Arizona, United States
Santa Monica, California, United States
Cleveland, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gordon MS, Rosen LS, Mendelson D, Ramanathan RK, Goldman J, Liu L, Xu Y, Gerson SL, Anthony SP, Figg WD, Spencer S, Adams BJ, Theuer CP, Leigh BR, Weiss GJ. A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2013 Jun;31(3):714-23. doi: 10.1007/s10637-012-9876-9. Epub 2012 Sep 29.
Related Links
Access external resources that provide additional context or updates about the study.
TRACON Pharmaceuticals Inc. Web Site
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
102ST101
Identifier Type: -
Identifier Source: org_study_id